Curaleaf Holdings (CURA) AI Stock Analysis

• Market Cap: $3.35B
• Dividend Yield: N/A
• Average Volume (3M): 832.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.51
• Revenue Growth: -2.64%
• EPS Growth: 1.65%
• Country: CA
• Employees: 5,519
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 670,458,400
• 10 Day Avg. Volume: 1,059,258
• 30 Day Avg. Volume: 832,373
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 1.76
• Enterprise Value/Gross Profit: 3.61
• Enterprise Value/Ebitda: 10.27
• 1Y Price Target: $4.52
• Price Target Upside: 2.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: C$3.50 ▼(-20.81% Downside)

Curaleaf Holdings' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and cash flow issues. While technical analysis shows positive momentum, the valuation metrics are poor due to negative earnings. The earnings call provides a mixed outlook with strong international growth but significant domestic and regulatory challenges.

Positive Factors

Market Expansion

Expansion into new markets is anticipated to increase revenue streams.

Operational Efficiency

Operational efficiencies are expected to drive margins.

Sales Growth

Sales growth in 2Q24 was largely driven by wholesale revenue growth as the international segment continues to gain traction.

Negative Factors

Competition

The company is facing stiff competition in the cannabis industry.

Financial Performance

EBITDA margins fell short of expectations due to higher G&A spend and heavy promotions at the start of the quarter.

Regulatory Challenges

There are concerns about regulatory challenges in the cannabis market.

Curaleaf Holdings Business Overview & Revenue Model

Company Description

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. In addition, it offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. Further, the company provides hemp-based CBD and cannabigerol products. The company was founded in 2010 and is headquartered in New York, New York.

How the Company Makes Money

Curaleaf generates revenue primarily through the sale of cannabis products in its dispensaries. This includes a diverse product range comprising dried flower, pre-rolls, edibles, concentrates, and topicals, which cater to both medical and recreational consumers. The company's revenue model is supported by its vertically integrated operations, allowing it to control production costs and quality. Additionally, Curaleaf benefits from strategic partnerships and collaborations with other cannabis brands and companies, enhancing its product offerings and market presence. The company's expansion into new states and markets, along with its emphasis on compliance and regulatory adherence, also contribute significantly to its earnings.

Curaleaf Holdings Financial Statement Overview

Summary

Curaleaf Holdings faces challenges with profitability, as evidenced by declining revenues and persistent net losses. While there is some improvement in cash flow and operational efficiency, the high debt levels and leverage risks pose financial stability concerns. The company needs to focus on enhancing profitability and managing leverage to ensure sustainable growth.

Income Statement

The company shows a declining revenue trend with a slight drop in total revenue from $1.34 billion in the previous year to $1.31 billion in TTM. The gross profit margin has decreased, indicating increased cost pressures. Furthermore, negative net income results in a negative net profit margin, highlighting ongoing profitability challenges. Though EBIT and EBITDA margins show slight improvements, they remain low, impacting overall profitability.

Balance Sheet

The balance sheet shows a relatively high debt-to-equity ratio, which poses leverage risks. However, the equity ratio remains stable, suggesting a moderate level of equity financing. Return on equity is negative due to net losses, impacting shareholder returns. Overall, the balance sheet shows stability but with notable leverage risks.

Cash Flow

Operating cash flow remains positive, reflecting operational viability. The free cash flow has grown compared to previous periods, improving cash flow stability. However, the free cash flow to net income ratio is affected by persistent losses, and the operating cash flow to net income ratio indicates inefficiencies. Overall, cash flow management shows improvements but remains constrained by net income losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.34B	1.35B	1.34B	1.21B	626.64M
Gross Profit	625.61M	639.25M	614.45M	579.03M	687.59M	390.51M
EBITDA	220.14M	233.14M	238.76M	220.97M	278.98M	128.59M
Net Income	-244.34M	-215.42M	-281.20M	-376.93M	-109.13M	-61.33M
Balance Sheet
Total Assets	2.92B	2.95B	3.10B	3.41B	3.11B	2.39B
Cash, Cash Equivalents and Short-Term Investments	102.27M	93.03M	91.82M	163.18M	299.33M	73.54M
Total Debt	843.02M	853.82M	883.55M	931.91M	652.40M	577.71M
Total Liabilities	1.98B	1.96B	1.93B	2.01B	1.44B	1.01B
Stockholders Equity	871.30M	861.21M	1.05B	1.28B	1.55B	1.38B
Cash Flow
Free Cash Flow	49.54M	64.42M	5.05M	-91.96M	-205.92M	-113.92M
Operating Cash Flow	136.37M	162.57M	75.26M	46.40M	-33.96M	12.36M
Investing Cash Flow	-87.48M	-93.83M	-78.69M	-228.62M	-163.97M	-197.11M
Financing Cash Flow	-37.76M	-54.24M	-67.02M	50.54M	424.80M	224.08M

Curaleaf Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CURA, the sentiment is Positive. The current price of 4.42 is above the 20-day moving average (MA) of 3.37, above the 50-day MA of 2.17, and above the 200-day MA of 1.87, indicating a bullish trend. The MACD of 0.63 indicates Negative momentum. The RSI at 71.72 is Negative, neither overbought nor oversold. The STOCH value of 91.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CURA.

Curaleaf Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CURA	56 Neutral	$3.35B	―	-24.93%	―	-2.64%	1.65%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
CGC	―	$388.80M	―	-98.42%	―	―	―
ACB	―	$299.85M	97.05	-0.70%	―	―	―
CRON	―	$977.31M	53.68	1.73%	―	―	―
TCNNF	―	$1.71B	―	-12.60%	―	―	―
CRLBF	―	$626.29M	―	-10.02%	―	―	―

Curaleaf Holdings Corporate Events

Curaleaf Expands Internationally Amidst Strong Q2 2025 Performance

Curaleaf Holdings reported a second-quarter 2025 revenue of $315 million, with a notable 62% year-over-year growth in its international segment. The company was awarded a license to operate in Turkey, marking a significant expansion in its international operations. Despite a net loss, Curaleaf is focusing on strategic growth, including opening new retail locations, launching innovative products, and strengthening its leadership team to position itself for future industry growth.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf to Announce Q2 2025 Financial Results

Curaleaf Holdings announced it will release its second quarter 2025 financial and operational results on August 6, 2025, after market close. The announcement will be followed by a conference call and webcast, providing stakeholders with insights into the company’s performance and strategic direction. This release is significant for stakeholders as it offers an opportunity to gauge Curaleaf’s market positioning and operational progress in the evolving cannabis industry.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Acquires Full Ownership of European Operations

Curaleaf Holdings has acquired the remaining equity stake in Curaleaf International Holdings Limited from a strategic institutional investor, bringing its ownership to 100%. This acquisition, completed through a Put/Call Option agreement, allows Curaleaf to streamline decision-making and enhance strategic alignment across its European operations, reinforcing its commitment to international expansion and long-term shareholder value.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Strengthens Leadership with New President and Key Executive Hires

Curaleaf Holdings has appointed Rahul Pinto as the new President to lead its global commercial functions, alongside strengthening its leadership team with three new Senior Vice Presidents in digital, retail merchandising, and brand marketing. This strategic move aims to enhance Curaleaf’s position as a global leader in the cannabis industry by leveraging Pinto’s extensive experience in consumer packaged goods and retail, as well as the expertise of the new hires, to drive innovation and growth.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Confirms Board and Auditor at 2025 AGM

Curaleaf Holdings, Inc. recently held its 2025 Annual General Meeting of Shareholders, where key resolutions were passed, including the election of ten directors and the reappointment of PKF O’Connor Davies, LLP as the company’s auditor. The meeting, conducted via webcast, saw significant shareholder participation with over 1.7 billion votes cast. These decisions are expected to reinforce Curaleaf’s governance and operational strategies, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Strengthens Governance at 2025 Annual Meeting

Curaleaf Holdings, Inc. held its 2025 Annual General Meeting of Shareholders via webcast, where key resolutions were passed, including the election of directors and the reappointment of the company’s auditor. The meeting saw a significant number of votes cast, reflecting strong shareholder engagement. These developments are expected to reinforce Curaleaf’s governance and operational stability, positively impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.